Niva Bupa Health Insurance Company
- Market Cap
- ₹13,754 Cr
- P/E
- 39.76
Key Fundamentals
MicrocapInsuranceFinancial ServicesPrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 3.15%
- Debt to Equity
- 0.07
- EPS (TTM)
- ₹1.87
- Book Value
- ₹20.78
- Market Cap
- ₹13,754 Cr
- P/E (TTM)
- 39.76
- P/B
- 3.58
- ROE
- 3.46%
- Dividend Yield
- 0.00%
- EBITDA
- ₹163 Cr
- 52W High
- ₹91.40
- 52W Low
- ₹67.50
- Day Range
- ₹73.13 – ₹74.50
- Volume
- 4,76,069
Peer Comparison
Financial Services › Insurance › General Insurance
| 1,736.00 | 33.90 | 86,733 | 4.61 | 0.43% | 16.60% | 21.90% | 29,038 | 2,555 | |
| 332.30 | 6.50 | 58,299 | 0.79 | 3.91% | 14.60% | 17.40% | 54,993 | 8,969 | |
| 556.05 | 31.05 | 32,730 | 3.14 | 0.00% | 7.61% | 9.69% | 20,056 | 1,054 | |
| 152.63 | — | 25,153 | 0.89 | 1.00% | 4.92% | 4.29% | 50,234 | −528 | |
| 239.00 | 27.25 | 22,111 | 2.72 | 0.00% | 12.20% | 13.10% | 11,994 | 810 | |
| 74.36 | 39.76 | 13,754 | 3.58 | 0.00% | 3.46% | 3.15% | 8,905 | 345 | |
| Median 6 companies | 285.65 | 31.05 | 28,942 | 2.93 | 0.22% | 9.91% | 11.40% | 24,547 | 932 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 97/100
Category scores
- Quality
- 32
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 37
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 84
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 27
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 19
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 59
- Good
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has delivered good profit growth of 35.9% CAGR over last 5 years
Weaknesses
3- Stock is trading at 3.58 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 5.20% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 6 | 1 |
| Oscillators | Bearish | 2 | 6 | 1 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bearish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 45.18
- Neutral
- MACD (12,26,9)
- −0.23
- Bearish
- SMA (50)
- 76.37
- Bearish
- SMA (200)
- 79.38
- Bearish
As of
Analyst Rating
9 of 10 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 5Y | +36.50% |
|---|---|
| 3Y | +32.89% |
| 1Y | +24.58% |
| TTM | +28.87% |
Net profit
| 5Y | Turned to profit |
|---|---|
| 3Y | +115.99% |
| 1Y | −38.79% |
| TTM | −1.71% |
Operating cash flow
| 5Y | +28.63% |
|---|---|
| 3Y | +15.13% |
| 1Y | −45.28% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | +3.95 pp |
|---|---|
| 3Y | +13.96 pp |
| 1Y | +0.85 pp |
| TTM | −0.78 pp |
Revenue by year
| Mar 2019 | ₹851 Cr |
|---|---|
| Mar 2020 | ₹1,057 Cr |
| Mar 2021 | ₹1,413 Cr |
| Mar 2022 | ₹1,877 Cr |
| Mar 2023 | ₹2,853 Cr |
| Mar 2024 | ₹4,115 Cr |
| Mar 2025 | ₹5,374 Cr |
| Mar 2026 | ₹6,695 Cr |
Net profit by year
| Mar 2019 | −₹48.00 Cr |
|---|---|
| Mar 2020 | −₹62.00 Cr |
| Mar 2021 | −₹50.00 Cr |
| Mar 2022 | −₹197 Cr |
| Mar 2023 | ₹13.00 Cr |
| Mar 2024 | ₹82.00 Cr |
| Mar 2025 | ₹214 Cr |
| Mar 2026 | ₹131 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Niva Bupa Health Insurance trades at ₹74 per share as of 2026-11-19 with a market cap of ₹13,687 crore. The company has demonstrated strong compounded sales growth of 33% over 3 years and 36% over 5 years, but profitability metrics remain modest with a 3-year average ROE of 5% and a trailing twelve-month PE of 39.57x. The stock is down roughly 19% from its 52-week high of ₹91.4.
- The company is virtually debt free with a debt-to-equity ratio of just 0.07, providing significant financial flexibility and resilience against adverse market conditions.
- Compounded sales growth stands at 33% over 3 years and 36% over 5 years, reflecting strong and sustained top-line momentum in a structurally underpenetrated health insurance market.
- Compounded profit growth of 127% over 3 years indicates a sharp improvement in the company's ability to convert revenue growth into bottom-line gains.
- 5-year compounded profit CAGR of 35.9% demonstrates consistent long-term earnings expansion well above broader market growth rates.
- TTM revenue growth of 29% shows the company continues to scale at a healthy pace even on a larger base.
- India's health insurance penetration remains low relative to global peers, providing a long structural growth runway for established players in the sector.
- The stock trades at 3.56 times book value, which is rich for a company generating a return on equity of only 3.45% on a trailing basis.
- Return on equity has been consistently low at 5% over 3 years, 3% over 5 years, and 3% in the last year, indicating the company is not generating strong returns on shareholders' capital.
- ROCE stands at -2.9%, suggesting the company's overall capital deployment is currently not generating positive returns when considering total capital employed.
- Despite reporting repeated profits, the company pays zero dividend (0% yield), returning no cash to shareholders.
- TTM profit growth has turned negative at -2%, signalling a potential deceleration or margin compression after a period of rapid earnings expansion.
- The 1-year stock CAGR of -4% indicates the market has de-rated the stock over the past year, reflecting waning investor sentiment.
- EPS of ₹1.87 on a share price of ₹74 implies investors are paying a steep premium per rupee of current earnings, amplifying downside risk if growth disappoints.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Niva Bupa is on a strong growth trajectory with Q2FY27 net profit doubling and revenue up 27% YoY on robust premium momentum. The launch of Meridian and early NCD redemption reflect product expansion and balance-sheet discipline. No material headwinds emerged in the period. Key to watch is whether premium growth sustains through H2FY27 and whether the expanded ESOP pool leads to meaningful dilution.
- Q2 net profit doubles YoY Nov 4
Niva Bupa posted net profit of ₹13.56 crore in Q2FY27, up 124% YoY. Revenue rose 27% to ₹241.23 crore on strong premium growth.
- Meridian product launched Nov 18
Niva Bupa launched Meridian on November 18, 2026, a health insurance product offering both domestic and international coverage, broadening its product suite.
- ₹150 crore NCD redemption Nov 13
Completed full redemption of ₹150 crore non-convertible debentures via call option on November 13, 2026, reducing debt on the balance sheet.
- ESOP pool doubling proposed Nov 17
Niva Bupa proposes adding 3.90 crore options to raise the ESOP 2024 pool to 7.72 crore. Shareholder voting runs November 19 to December 18, 2026.
- Investor conference participation Nov 10
Niva Bupa will participate in investor conferences in Mumbai on November 17 and 18, 2026, signalling active engagement with the investment community.
- UPSI policies consolidated Nov 4
Board approved merging its Fair Disclosure and Leak Inquiry policies into a single document under SEBI guidelines, a routine governance update.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 969 | 1,026 | 1,316 | 1,124 | 1,321 | 1,258 | 1,671 | 1,932 | 2,049 | 1,611 | 2,251 | 2,471 | 2,572 |
| Expenses | 1,027 | 1,071 | 1,215 | 1,228 | 1,387 | 1,282 | 1,420 | 1,834 | 1,967 | 1,705 | 2,069 | 2,287 | 2,389 |
| Operating Profit | −58 | −46 | 100 | −103 | −66 | −24 | 251 | 98 | 82 | −94 | 182 | 184 | 183 |
| OPM % | −6% | −4.4% | 8% | −9% | −5% | −1.9% | 15% | 5% | 4% | −6% | 8% | 7% | 7% |
| Other Income | 50 | 50 | 57 | 84 | 79 | 37 | −45 | 0 | 0 | 7 | −1 | 0 | −2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | −8 | 5 | 157 | −19 | 13 | 13 | 206 | 98 | 82 | −88 | 181 | 184 | 182 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 27% | 26% | 0% | 12% | 25% | 25% |
| Net Profit | −8 | 5 | 157 | −19 | 13 | 13 | 206 | 71 | 61 | −88 | 159 | 138 | 136 |
| EPS (₹) | — | — | — | — | — | 0.07 | 1.13 | 0.39 | 0.33 | −0.47 | 0.86 | 0.75 | 0.73 |
| YoY Sales growth | — | — | — | — | 36 | 23 | 27 | 72 | 55 | 28 | 35 | 28 | 26 |
Profit & Loss
₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 851 | 1,057 | 1,413 | 1,877 | 2,853 | 4,115 | 5,374 | 6,695 | 8,905 |
| Expenses | 880 | 1,094 | 1,435 | 2,328 | 3,183 | 4,228 | 5,292 | 6,534 | 8,450 |
| Operating Profit | −29 | −37 | −22 | −451 | −330 | −113 | 83 | 160 | 455 |
| OPM % | −3.4% | −3.5% | −1.5% | −24% | −12% | −2.7% | 1.5% | 2.4% | 5% |
| Other Income | 0 | 0 | 0 | 281 | 374 | 224 | 155 | 1.34 | 3 |
| Interest | 3 | 4 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 16 | 21 | 22 | 27 | 32 | 29 | 25 | 36 | 0 |
| PBT | −48 | −62 | −50 | −197 | 13 | 82 | 214 | 127 | 458 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | −3% | — |
| Net Profit | −48 | −62 | −50 | −197 | 13 | 82 | 214 | 131 | 345 |
| EPS (₹) | — | — | — | — | — | — | 1.17 | 0.71 | 1.87 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Sales growth | — | 24 | 34 | 33 | 52 | 44 | 31 | 25 | 29 |
Balance Sheet
₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 981 | 1,126 | 1,350 | 1,409 | 1,511 | 1,700 | 1,827 | 1,847 | 1,850 |
| Reserves | −719 | −780 | −773 | −903 | −683 | 351 | 1,949 | 1,939 | 1,994 |
| Borrowings | 0 | 0 | 0 | 250 | 250 | 250 | 250 | 250 | 268 |
| Other Liabilities | 737 | 891 | 1,322 | 1,983 | 2,799 | 3,891 | 5,735 | 7,240 | 8,017 |
| Total Liabilities | 1,000 | 1,237 | 1,899 | 2,738 | 3,877 | 6,192 | 9,760 | 11,276 | 12,128 |
| Fixed Assets | 30 | 39 | 46 | 49 | 52 | 58 | 66 | 85 | 180 |
| CWIP | 2 | 2 | 2 | 1 | 4 | 1 | 9 | 3 | 0 |
| Investments | 816 | 1,067 | 1,622 | 2,401 | 3,366 | 5,458 | 8,175 | 9,670 | 10,659 |
| Other Assets | 152 | 129 | 230 | 287 | 455 | 675 | 1,510 | 1,518 | 1,288 |
| Total Assets | 1,000 | 1,237 | 1,899 | 2,738 | 3,877 | 6,192 | 9,760 | 11,276 | 12,128 |
Cash Flow
₹ Cr| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | — | — | 257 | 338 | 593 | 813 | 1,654 | 905 |
| Investing | — | — | −374 | −723 | −829 | −1,882 | −2,348 | −961 |
| Financing | — | — | 280 | 374 | 280 | 1,110 | 771 | −5 |
| Net Cash Flow | — | — | 164 | −12 | 43 | 41 | 78 | −62 |
| Free Cash Flow | — | — | 229 | 309 | 555 | 780 | 1,614 | 857 |
| CFO/EBITDA | — | — | −1,180 | −75 | −180 | −720 | 2,000 | 577 |
Ratios
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Conversion Cycle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Capital Days | −264 | −270 | −290 | −341 | −313 | −298 | −351 | −354 |
| ROCE % | — | −19% | −10% | −30% | 1% | 5% | 7% | 3% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Niva Bupa Health Insurance Company insights
31 extracted metrics across FY19–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT
- Q3 FY26 concall · Feb 2026Transcript PPT
- 15 Oct 2026
- 21 Aug 2026
- 16 Jul 2026
- 26 Jun 2026
- 27 Jun 2025
- General announcements 18 Nov 2026
- General announcements 13 Nov 2026
- General announcements 13 Nov 2026
Frequently Asked Questions about Niva Bupa Health Insurance Company
What does Niva Bupa Health Insurance Company Ltd do?
Where is Niva Bupa Health Insurance Company Ltd (NIVABUPA) listed?
Which sector does Niva Bupa Health Insurance Company Ltd belong to?
What is the market capitalisation of Niva Bupa Health Insurance Company Ltd?
What is the PE ratio of Niva Bupa Health Insurance Company Ltd?
What is the 52-week high and low of Niva Bupa Health Insurance Company Ltd?
What is the Return on Equity (ROE) of Niva Bupa Health Insurance Company Ltd?
Company Information
Incorporated in 2008, Niva Bupa Health Insurance Ltd is a Tech driven leading health insurer in India.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NIVABUPA.md for Niva Bupa Health Insurance Company Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.